23 Apr 2008 - Kinaxo Biotechnologies announced that it has entered an agreement with Takeda San Diego, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Osaka, Japan. Under the agreement, Kinaxo will make its KinaTor(TM) technology available to Takeda researchers involved in drug discovery, preclinical research and clinical development. Kinaxo's Cellular Target Profiling utilizes proprietary chemical proteomics technologies combined with state-of-the-art mass spectrometry to identify and characterize a drug candidate's native molecular targets in cell lines and tissue samples.
""We consider this agreement with Takeda, the leading R&D-oriented pharmaceutical company of Japan, to be a major progress in the world-wide expansion of our business", said Dr. Andreas Jenne, tthe chief executive officer of Kinaxo. "We continue to demonstrate the validation of the KinaTor(TM) ttechnology by providing services to leading pharmaceutical and biotechnology companies, including Johnson& Johnson, Bayer-Schering, Takeda and UCB Pharma."
 |
www.bionity.com/news/e/81045 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/81045 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |